Results 161 to 170 of about 72,525 (247)

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, Volume 81, Issue 9, Page 3039-3070, September 2026.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
Franziska Roth‐Walter, Ian M. Adcock, Cristina Benito‐Villalvilla, Rodolfo Bianchini, Leif Bjermer, Gaetano Caramori, Luigi Cari, Kian Fan Chung, Zuzana Diamant, Ibon Eguiluz‐Gracia, Edward F. Knol, Milos Jesenak, Francesca Levi‐Schaffer, Giuseppe Nocentini, Liam O'Mahony, Oscar Palomares, Frank Redegeld, Milena Sokolowska, Betty Van Esch, Marco Zurlo, Cristiana Stellato   +20 more
wiley   +1 more source

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)

, 2008
1Martin Henkes, 2Heiko van der Kuip, 1Walter E Aulitzky12nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch Hospital, Auerbachstr. 110, Stuttgart, Germany; 2Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstr.
Walter E Aulitzky, Martin Henkes, Heiko van der Kuip   +2 more
core  

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 5, Page 625-634, September 2026.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE‐STOP219 study

British Journal of Haematology, Volume 209, Issue 3, Page 1111-1118, September 2026.
Summary Treatment‐free remission (TFR) is now a key goal for chronic‐phase chronic myeloid leukaemia (CML‐CP) after achievement of a prolonged deep molecular response. About half of these patients can remain in remission without treatment, whereas those who relapse must resume lifelong therapy.
Noriyoshi Iriyama, Naoto Takahashi, Katsumichi Fujimaki, Takaaki Ono, Masuho Saburi, Masahide Yamamoto, Fumihiko Kimura, Eisei Kondo, Nobuyuki Aotsuka, Hiroki Yokoyama, Seiichiro Katagiri, Yosuke Minami, Maho Ishikawa, Yachiyo Kuwatsuka, Masatomo Miura, Akiko M. Saito, Toshiki I. Saito, Itaru Matsumura, Yasushi Miyazaki, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Hitoshi Kiyoi   +22 more
wiley   +1 more source

Synthesis, Structural Characterization, and Investigation of Biological Effects of Novel Benzothiazole‐Triazole Derivatives Designed as AKT Kinase Inhibitors

Chemical Biology &Drug Design, Volume 108, Issue 3, September 2026.
Novel benzothiazole‐triazole derivatives were designed and synthesized as potential anticancer agents targeting the PI3K/Akt pathway. Compound 5h exhibited potent Akt1 inhibition, induced apoptosis and mitochondrial dysfunction in MCF‐7 cells, and demonstrated stable binding in molecular docking and dynamics studies, highlighting its promise for breast
Bilge Çiftçi, Zeynep Gülenç, Büşra Korkut Çelikateş, Derya Osmaniye   +3 more
wiley   +1 more source

European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing—Recommendations on Best Practice (Update 2026)

Contact Dermatitis, Volume 95, Issue 3, Page 237-275, September 2026.
ABSTRACT The present guideline updates the initial ESCD patch testing guideline, summarizing all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed‐type hypersensitivity skin and mucosal conditions. Sections with brief descriptions
Wolfgang Uter, Olivier Aerts, Tove Agner, Richard Brans, Magnus Bruze, Alicia Cannavó, Marie‐Noёlle Crépy, Ana M. Giménez‐Arnau, Margarida Gonçalo, An Goossens, Swen M. John, Carola Lidén, Suzana Ljubojević Hadžavdić, Vera Mahler, Mihaly Matura, Esen Özkaya, Maria Pesonen, Nadia Raison‐Peyron, Thomas Rustemeyer, Radoslaw Spiewak, Luca Stingeni, Ian R. White, S. Mark Wilkinson, Jeanne Duus Johansen   +23 more
wiley   +1 more source

Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Early clinical development of anticancer drugs traditionally focused on exploring candidate treatments in patients. For instance, due to their cytotoxic action, administration of chemotherapies to healthy volunteers (HVs) for evaluation of their pharmacokinetic profiles was not considered feasible nor ethical from a safety and tolerability ...
Aernout D. van Haarst, Sabina Paglialunga, Ziv Machnes, Ikuo Yamamiya, Nanae Hangai, Aram Oganesian   +5 more
wiley   +1 more source

A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia

Journal of Cutaneous Pathology, Volume 53, Issue 9, Page 767-771, September 2026.
ABSTRACT Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML).
Bennett Christie‐Nguyen, Hanadi El Achi, Levani Iashvili, Amer Wahed, Brenda Mai, Jacob Armstrong   +5 more
wiley   +1 more source

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

The FEBS Journal, Volume 293, Issue 17, Page 5107-5120, September 2026.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma, Mark T. S. Williams   +1 more
wiley   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source